fluoxetine has been researched along with Blindness in 1 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Blindness: The inability to see or the loss or absence of perception of visual stimuli. This condition may be the result of EYE DISEASES; OPTIC NERVE DISEASES; OPTIC CHIASM diseases; or BRAIN DISEASES affecting the VISUAL PATHWAYS or OCCIPITAL LOBE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambati, M | 1 |
| Apicella, I | 1 |
| Wang, SB | 1 |
| Narendran, S | 1 |
| Leung, H | 1 |
| Pereira, F | 1 |
| Nagasaka, Y | 1 |
| Huang, P | 1 |
| Varshney, A | 1 |
| Baker, KL | 1 |
| Marion, KM | 1 |
| Shadmehr, M | 1 |
| Stains, CI | 1 |
| Werner, BC | 1 |
| Sadda, SR | 1 |
| Taylor, EW | 1 |
| Sutton, SS | 1 |
| Magagnoli, J | 1 |
| Gelfand, BD | 1 |
1 other study available for fluoxetine and Blindness
| Article | Year |
|---|---|
Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration.
Topics: Alu Elements; Animals; Antidepressive Agents, Second-Generation; Blindness; Cell Line; Cytokines; De | 2021 |